Stock Code: 002603 Stock Abbreviation: Yiling Pharmaceutical Announcement No.: 2026-034
Shijiazhuang Yiling Pharmaceutical Co., Ltd.
Announcement on Company and Wholly-Owned Subsidiary's Patented Products Included in the National Essential Medicines List (2026 Edition)
The Company and the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed herein, and that there are no false records, misleading statements, or material omissions.
The National Health Commission released the "National Essential Medicines List (2026 Edition)" on July 9, 2026, which will take effect on September 1, 2026. Shijiazhuang Yiling Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") has verified that its patented products Tongxinluo Capsules, Lianhua Qingwen Capsules, Qili Qiangxin Capsules, Jinlida Granules, Jieyu Chufan Capsules, and its wholly-owned subsidiary Beijing Yiling Pharmaceutical Co., Ltd.'s patented product Songyang Shenxin Capsules and Lianhua Qingwen Granules have been included in the "National Essential Medicines List (2026 Edition)". The details are as follows:
| Drug Name | Dosage Form and Specifications |
|---|---|
| Tongxinluo Capsules | Capsules: 0.26g per capsule |
| Songyang Shenxin Capsules | Capsules: 0.4g per capsule |
| Qili Qiangxin Capsules | Capsules: 0.3g per capsule (equivalent to 1.90g of crude drug) |
| Jinlida Granules | Granules: 9g per bag |
| Lianhua Qingwen Capsules (Granules) | Capsules: 0.35g per ca |